Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_7544_T2_RNA

— · A

2e0a68a5-1c76-59c3-a979-9436bc584ea9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • WNT_BETA_CATENIN_SIGNALING+0.440
  • UV_RESPONSE_DN+0.420
  • MYOGENESIS+0.390
  • HEDGEHOG_SIGNALING+0.360
  • ADIPOGENESIS+0.310
  • APICAL_JUNCTION+0.300
  • PANCREAS_BETA_CELLS+0.300
  • NOTCH_SIGNALING+0.280
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
  • COAGULATION+0.250

Top 10 suppressed

  • E2F_TARGETS-0.580
  • G2M_CHECKPOINT-0.510
  • INTERFERON_ALPHA_RESPONSE-0.460
  • MTORC1_SIGNALING-0.460
  • MYC_TARGETS_V2-0.440
  • PI3K_AKT_MTOR_SIGNALING-0.340
  • UNFOLDED_PROTEIN_RESPONSE-0.340
  • GLYCOLYSIS-0.330
  • MYC_TARGETS_V1-0.330
  • INTERFERON_GAMMA_RESPONSE-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A0EA-01A-11R-A115-07
breast-umap@18
—A0.938
2MBCProject_0063_T3A_RNA
breast-umap@18
—A0.928
3TCGA-BH-A28O-01A-11R-A22K-07
breast-umap@18
—A0.885
4TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.877
5SRR8613732
breast-umap@18
—A0.865
6BSR_05_0025_A4_S57
breast-umap@18
—A0.862
7SRR1313091
breast-umap@18
—A0.841
8MBCProject_1078_T2_RNA
breast-umap@18
—A0.832
9SRR26320067
bladder-landscape@3
——0.828
10SRR35579834
breast-umap@18
—A0.827

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
WNT_BETA_CATENIN_SIGNALING0.440Inavolisib— uncovered
UV_RESPONSE_DN0.420Inavolisib— uncovered
MYOGENESIS0.390Inavolisib— uncovered
HEDGEHOG_SIGNALING0.360Inavolisib— uncovered
ADIPOGENESIS0.310Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
NOTCH_SIGNALING0.280Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
COAGULATION0.250Binimetinib— uncovered
KRAS_SIGNALING_DN0.230Remibrutinib— uncovered
KRAS_SIGNALING_UP0.220Inavolisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
HYPOXIA0.190Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.190Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.190Inavolisib— uncovered
ANGIOGENESIS0.180Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
BILE_ACID_METABOLISM0.160Inavolisib— uncovered
APICAL_SURFACE0.080Temsirolimus— uncovered